tiprankstipranks
Viking Therapeutics (VKTX)
NASDAQ:VKTX
US Market

Viking Therapeutics Income Statement

Last quarter (Q3 2024), Viking Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Viking Therapeutics's net income was $-24.94M. See Viking Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ ―$ ―$ ―$ ―$ ―
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ ―$ ―$ ―$ ―$ ―
EBITDA
$ -100.53M$ -70.06M$ -55.39M$ -42.38M$ -24.76M
Operating Income
$ -100.83M$ -70.36M$ -55.68M$ -42.66M$ -32.69M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -85.89M$ -68.87M$ -54.99M$ -39.49M$ -25.78M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Viking Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis